Use access key #2 to skip to page content.
$18.02 0.23 (1.29%)
8/28/2008 11:49 AM

Cepheid (CPHD)

CAPS Rating:
***

A molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the Clinical Molecular Diagnostic, Industrial and Biothreat markets.

View Ticker Page (CPHD)

Results 1 - 10 of 45 :   12345

Recs

5

Avatar hellerbrewing (85.32) Submitted: 8/09/07 4:22 PM : Outperform Start Price: $17.99 CPHD Score: 10.49

Cepheid manufactures equipment that sets itself apart from its competitors. For those in the diagnostic field such as myself, their smartcycler 2 is really the only game in town. With the constant threat of biological attacks as well as the increas...

Report this Post Replies: 0 | Reply | Permalink

Recs

4

Avatar NetscribeTech (47.87) Submitted: 1/25/07 8:21 AM : Outperform Start Price: $8.23 CPHD Score: 128.94

Cepheid is a molecular diagnostic solutions company, specializing in designing, developing and marketing fully integrated systems for genetic and molecular analysis that can be used in clinical and molecular diagnosis, industrial and bio-threat marke...

Report this Post Replies: 0 | Reply | Permalink

Recs

4

Avatar TMFBreakerJava (99.23) Submitted: 5/12/08 10:56 PM : Outperform Start Price: $25.31 CPHD Score: -21.03

This company sells a near-real time Staph tester which can be a life saver in this new era of superbugs. Their tech displaces tests that take 24 to 48 hours to provide results. Thanks to bigredchet for bringing this one to my attention.

Demand can...

Report this Post Replies: 0 | Reply | Permalink

Recs

3

Avatar 21popsontop (22.75) Submitted: 1/25/08 5:23 AM : Underperform Start Price: $32.50 CPHD Score: 39.42

Every year many stocks get pumped up on hype in one way or another.Everything from save the world to new cures for lockjaw. This tradition is older than I am and the markets are loaded with these company's.If They gain market hype then they are mostl...

Report this Post Replies: 0 | Reply | Permalink

Recs

2

Avatar whakojacko (97.84) Submitted: 8/26/07 1:11 PM : Outperform Start Price: $15.26 CPHD Score: 34.11

Genxpert is an amazing platform will likely be in the majority of hospitals if its success continues as it is a very well designed product with little competition. CPHD is not profitable now largely because of massive R&D costs (~25% of expenses) goi...

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar tenmiles (99.96) Submitted: 8/08/07 9:56 AM : Underperform Start Price: $18.30 CPHD Score: -11.45

I would sell this billion cap baby at $17; second quarter loss narrowed, but technically overdone here - look for buying oppt. in the $14-15 range within next two quarters.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar wsdick (< 20) Submitted: 8/25/07 6:28 PM : Outperform Start Price: $18.70 CPHD Score: 8.79

These guys got their foot in the door prior to the anthrax scares and were in try-out phase when the letters hit. Now Northrup has picked them up for 5 years to cover USPS processing stations. The technology transplants easily into medical diagnostic...

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar ashlissa (49.04) Submitted: 8/29/07 4:48 PM : Outperform Start Price: $18.21 CPHD Score: 9.94

A fantastic growth stock. Poised to grow over 15% per annum over the next five years.


Their Genxpert system is the best system available, and even with the recent runup in price, the FDA clearence of the various tests and the system it...

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar bclan13 (99.73) Submitted: 3/31/08 11:01 PM : Outperform Start Price: $24.40 CPHD Score: -23.01

I think Cepheid is building a solid competitive advantage in nosocomial infection surveillance / screening / diagnostics; I feel that it will be difficult to beat CPHD both on the low end and the high end:

Low End: As the Company's install...

Report this Post Replies: 0 | Reply | Permalink

Recs

1

Avatar PlanetBuffet (87.91) Submitted: 11/01/07 4:50 PM : Outperform Start Price: $13.09 CPHD Score: 49.34

CPHD reporting 3rd quarter earning today (11-1-07). Total revenues up 53% compared to 3rd quarter 2006 due mainly to their new "GeneXpert(R) System" which provides rapid detection of Methicillin- resistant Staphylococcus aureus (MRSA). MRSA has h...

Report this Post Replies: 0 | Reply | Permalink

Featured Broker Partners